Swapnil Shinkar | Formulation Science | Best Researcher Award

Swapnil Shinkar | Formulation Science | Best Researcher Award

Mr Swapnil Shinkar, National Institute of Technology Raipur, India

Mr. Swapnil Shinkar is a dedicated statistician and academician pursuing his Ph.D. in Statistics from NIT Raipur. With extensive teaching and research experience, he has served as a Statistician Cum Assistant Professor in various medical institutions, currently at Shri Shankaracharya Institute of Medical Sciences, Bhilai. Proficient in statistical software like SPSS, R, and MINITAB, he specializes in data analysis and research methodology. His work includes publications on queuing models and simulation approaches. Certified in Six Sigma Green Belt and Data Science, he actively contributes to statistical research and medical education. 📚📈

Publication Profile

orcid

Education

Mr. Swapnil Shinkar 🎓 is currently pursuing a Ph.D. in Statistics from the National Institute of Technology, Raipur, with his thesis submission expected after August 2025. He has already earned a Ph.D. in Statistics from Rashtrasant Tukadoji Maharaj Nagpur University (Notification: January 2024). He completed his M.Sc. in Statistics (2010-2012) and B.Sc. in Statistics (2005-2008) with commendable scores. His academic journey began at Nashik Board, where he completed his H.S.C. and S.S.C. 📊 Proficient in statistical software, he is skilled in SPSS, MINITAB, SyStat, R Programming, and MS Excel, making him a data-driven analytical expert. 📈

Experience

Mr. Swapnil Shinkar 🎓 is a seasoned statistician and academician with extensive experience in teaching and research. He is currently serving as a Statistician Cum Assistant Professor in the Department of Community Medicine at Shri Shankaracharya Institute of Medical Sciences, Bhilai (since July 2024). Previously, he held similar roles at Vedantaa Institute of Medical Sciences, Symbiosis Medical College for Women, and Pt. J. N. M. Medical College, contributing significantly to medical research and education. His journey also includes a Junior Research Fellowship (SERB) at RTM Nagpur University and experience as a Contributory Lecturer, shaping future researchers. 📊📚

Administrative Experience

Mr. Swapnil Shinkar 🎓 has extensive administrative experience in the medical and academic sectors. He served as a Regulatory Officer at Vedantaa Institute of Medical Sciences, Palghar, from March 2023 to June 2024, ensuring compliance and governance. Previously, he held the role of Nodal Officer at the same institute from July 2017 to February 2019, managing key responsibilities. Additionally, he was In-charge of the Medical Record Department at Shri Shankaracharya Institute of Medical Sciences, Bhilai, from September 2016 to June 2017. His leadership and organizational skills have significantly contributed to institutional operations. 🏥📊

Research Guidance

Mr. Swapnil Shinkar 🎓 has extensive experience in research guidance, particularly in statistical analysis. In the non-medical domain, he has mentored over 30 Ph.D. candidates, providing expert statistical insights. In the medical field, he has guided 15 undergraduate project groups in research planning and statistical analysis. Additionally, he supports more than 100 postgraduate medical candidates annually, assisting them in data analysis and research methodology. His expertise in statistics plays a crucial role in shaping high-quality research across multiple disciplines, making him a sought-after mentor and advisor in academic and medical research. 📊📚

Research Focus

Dr. Swapnil Shinkar’s research primarily focuses on public health epidemiology 🏥, community medicine 🌍, and infectious disease surveillance 🦠. His work spans hypertension prevalence among tribal populations, HIV risk factors, oral cancer screening, and COVID-19 studies. Additionally, he has contributed to biostatistics education, tuberculosis screening, and child development programs. His expertise extends to healthcare accessibility 🚑, disease prevention 🛑, and health policy evaluation 📊. Through cross-sectional and longitudinal studies, he provides critical insights into health disparities and medical education 📖. His multidisciplinary approach helps bridge the gap between epidemiology, healthcare interventions, and public health policies.

Publication Top Notes

Assoc Prof Dr. Ashok Behera|Pharmacy|Best Researcher Award

Assoc Prof Dr. Ashok Behera|Pharmacy |Best Researcher Award

Assoc Prof Dr. Ashok Behera at DIT University,India

PROFILE  

orcid

Google scholar

Early Academic Pursuits 🎓

Dr. Behera’s academic journey laid a solid foundation for his career in medicinal chemistry. After completing his 10th standard from H.Katapali High School in Odisha with first division honors, he pursued his 12th Science from the Council of Higher Secondary Education (CHSE), Odisha, in 2000. His early interest in chemistry and biology was evident in his undergraduate studies, where he earned a B.Pharm degree from Biju Pattnaik University of Technology (BPUT), Odisha, in 2007, with a CGPA of 8.33/10, reflecting his outstanding academic performance in subjects like pharmaceutical chemistry and pharmacology.

His academic journey reached new heights when he secured admission to the National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, for an M.S. (Pharm) in Medicinal Chemistry. During this time, he developed a deep interest in drug discovery, which culminated in his thesis titled “Synthesis of Biologically Active Medium Ring Heterocycles using Amino Acid as Precursors.” With a CGPA of 9.46/10 (89.60%), he proved his prowess in medicinal chemistry and drug action principles.

In 2014, Dr. Behera was awarded a Ph.D. in Pharmacy from Jadavpur University, supported by his work at the CSIR-Indian Institute of Chemical Biology (IICB). His doctoral thesis, titled “Synthesis of New Somatostatin Receptor Binding Radiolabeled Peptides: Physico-chemical and Biological Evaluation and Scintigraphic Studies,” explored innovative approaches in radiopharmaceutical development for cancer imaging, marking his entry into the specialized field of nuclear medicine.

Professional Endeavors and Research Focus 🔬

Dr. Behera’s professional career has been marked by both academic and research excellence. His career in academia began as an Assistant Professor at various prestigious institutions, including The M.S. University of Baroda and Himalayan Pharmacy Institute. His dedication to teaching and mentoring students was complemented by his extensive research work, particularly in the fields of peptide chemistry and targeted drug delivery systems.

One of the key areas of Dr. Behera’s research includes peptidomimetics and peptide conjugates as therapeutics. His work has focused on the development of receptor-specific drug delivery mechanisms, especially in the realm of anticancer drug discovery. His expertise in solid-phase peptide synthesis and stapled peptide synthesis has allowed him to contribute significantly to the synthesis and purification of novel peptides with therapeutic potential.

His research further delves into computer-aided drug design (CADD), where he employs virtual docking techniques using tools like AutoDock Vina and Chimera. He has also demonstrated proficiency in various analytical techniques, including FT-IR, NMR, and Mass Spectrometry, making him a versatile figure in both synthetic and analytical chemistry.

Contributions to Science and Innovation 🌟

Dr. Behera has developed a reputation as a thought leader in medicinal chemistry, particularly through his research on radiolabeled peptides for cancer imaging. His groundbreaking work in synthesizing radiolabeled anticancer drugs for nuclear imaging has opened new avenues for targeted therapies in oncology. He has conducted extensive studies on in vitro assays, radioligand binding assays, and in vivo pharmacokinetic studies, pushing the boundaries of radiopharmaceutical development.

His contribution to biological studies is equally noteworthy, having worked on cell line assays, mechanistic studies, and tumor imaging via SPECT gamma cameras. His work in this domain aims to improve the precision of cancer diagnosis and treatment, combining both chemistry and biology to create innovative solutions.

Accolades and Recognition 🏆

Dr. Behera’s excellence in research and teaching has been recognized with numerous awards and fellowships. He was awarded the Young Researcher Award in 2010 by the Saha Institute of Nuclear Physics in collaboration with the International Atomic Energy Agency (IAEA). He has also won multiple awards for oral and poster presentations at national and international conferences, including the Best E-poster presentation at the 24th Annual Convention of the Association of Pharmaceutical Teachers of India (APTI) in 2019.

In addition to his awards, Dr. Behera is an active member of prestigious organizations like the Royal Society of Chemistry (MRSC) and serves as a mentor for the CSIR Summer Research Training Program.

Impact and Influence 🌍

Dr. Behera’s impact extends beyond his research and teaching. As a mentor, he has guided several students through complex research projects, helping them navigate the intricacies of medicinal chemistry and drug design. His involvement in interdisciplinary projects, such as the development of receptor-specific targeted drugs and nuclear imaging techniques, has made a lasting impression on the scientific community.

His work is frequently cited in scientific literature, as evidenced by his strong presence on platforms like Google Scholar, ResearchGate, and Publons. His contributions have influenced both academic research and practical applications in the pharmaceutical industry, particularly in cancer therapeutics and imaging.

Legacy and Future Contributions 🌱

As Dr. Behera continues his journey in academia and research, his legacy will be defined by his relentless pursuit of innovation in medicinal chemistry. His work on peptide therapeutics, drug delivery systems, and nuclear imaging is poised to influence future generations of researchers and professionals in the pharmaceutical sciences.

With ongoing research in radiopharmaceutical development and a growing focus on bio-conjugation techniques, Dr. Behera’s future contributions will likely address some of the most pressing challenges in modern medicine, particularly in cancer treatment. His dedication to both education and research ensures that his legacy will inspire innovation and discovery for years to come.

🎓Publication 

Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis-an updated review

  • Authors   :Taha Alqahtani, Sharada L Deore, Anjali A Kide, Bhavana A Shende, Ritika Sharma, Rita Dadarao Chakole, Lalita S Nemade, Nikita Kishor Kale, Sudarshana Borah, Savita Shrikant Deokar, Ashok Behera, Divya Dhawal Bhandari, Nikita Gaikwad, Abul Kalam Azad, Arabinda Ghosh
  • Journal    :Mitochondrion
  • Year         :2023

Copper-Catalyzed Electrophilic Ortho C(sp2)–H Amination of Aryl Amines: Dramatic Reactivity of Bicyclic System

  • Authors   :Hasina Mamataj Begam, Rajarshee Choudhury, Ashok Behera, Ranjan Jana
  • Journal    :Organic letters
  • Year         :2019

Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor‐positive tumor scintigraphy

  • Authors   :Kakali De, Arijit Bhowmik, Ashok Behera, Indranil Banerjee, Mrinal Kanti Ghosh, Mridula Misra
  • Journal    :Journal of Peptide Science
  • Year         :2012

Synthesis, radiolabelling and biodistribution of HYNIC-Tyr 3 octreotide: a somatostatin receptor positive tumour imaging agent

  • Authors   : Ashok Behera, Kakali De, Susmita Chandra, Sankha Chattopadhyay, Mridula Misra
  • Journal    :journal of Radioanalytical and Nuclear Chemistry
  • Year         :2011

Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of 99mTc-HYNIC-His3-Octreotate as novel …

  • Authors   : Ashok Behera, Indranil Banerjee, Kakali De, Rudra Narayan Munda, Sankha Chattopadhayay, Amalesh Samanta, Bharat Sarkar, Santanu Ganguly, Mridula Misra
  • Journal    :Amino Acids
  • Year         :2013

Prof. Fatma YURT|pharmaceuticals | Best Researcher Award

Prof. Fatma YURT |pharmaceuticals|Best Researcher Award|

Prof. Fatma YURT atEge University,Turkey

PROFILE  

scopus

Orcid

Early Academic Pursuits 🎓

Prof. Dr. Fatma Yurt’s journey into the scientific world began at Ege University, one of Turkey’s leading institutions. She completed her undergraduate studies at the Faculty of Science in the Department of Chemistry between 1982 and 1987. Her passion for science and dedication to learning set the stage for her illustrious career in nuclear sciences. Following her bachelor’s degree, she pursued a doctorate at Ege University in the Institute of Nuclear Sciences, specializing in Nuclear Sciences. From 1991 to 1998, she immersed herself in the study of nuclear applications, gaining a deep understanding of the field’s complexities and potential. This period of intense academic focus and research laid a solid foundation for her future contributions to nuclear medicine, radiopharmacy, and related fields.

Professional Endeavors 💼

Prof. Dr. Fatma Yurt’s professional career is marked by her steady rise through the academic ranks at Ege University. She began her career as a Research Assistant in the Nuclear Applications Department of the Institute of Nuclear Sciences, where she served from 1994 to 1997. This role allowed her to engage in cutting-edge research and contribute to the development of nuclear sciences in Turkey.

In 1999, she was promoted to Assistant Professor, and later in the same year, she achieved the rank of Associate Professor. Her commitment to education and research was evident as she continued to mentor students and lead research projects in nuclear applications. By 2007, she had earned the title of Professor, solidifying her position as a leading expert in her field.

Prof. Dr. Yurt’s expertise is not limited to academia; she has also held significant administrative roles. Since 2016, she has served as the Director of the Institute of Nuclear Sciences at Ege University. In this capacity, she has been instrumental in shaping the direction of nuclear research and education in Turkey, overseeing various projects and initiatives that have expanded the institute’s influence both nationally and internationally.

Contributions and Research Focus 🔬

Prof. Dr. Fatma Yurt’s research spans several critical areas within nuclear sciences, with a particular emphasis on nuclear medicine, radiopharmacy, and pharmacology. Her work in these fields has been pivotal in advancing the understanding and application of nuclear techniques in medicine, particularly in diagnosing and treating various diseases.

Her research contributions include the development of novel radiopharmaceuticals, which are essential for diagnosing and treating conditions such as cancer. Prof. Dr. Yurt’s expertise in nuclear chemistry and physical chemistry has enabled her to explore the intricate processes involved in the synthesis and application of these compounds. She has also contributed significantly to the field of health sciences, particularly in the areas of internal medicine and pharmaceutical technology.

With a Scopus publication count of 123 and a Unisis publication count of 296, Prof. Dr. Yurt’s research output is impressive. Her work has been cited over 1,447 times on Scopus, reflecting the impact and relevance of her research. Her H-Index, a measure of both the productivity and citation impact of her publications, stands at 21 on Scopus, further underscoring her influence in the field.

Accolades and Recognition 🏆

Throughout her career, Prof. Dr. Fatma Yurt has received numerous accolades and recognition for her contributions to nuclear sciences and medicine. Her research has been widely acknowledged by her peers, and she has been invited to present her findings at various national and international conferences. Her role as the Director of the Institute of Nuclear Sciences is a testament to her leadership abilities and her dedication to advancing the field of nuclear applications.

Prof. Dr. Yurt’s work has not only advanced scientific understanding but has also had a tangible impact on healthcare. Her contributions to radiopharmacy have been particularly significant, with her research playing a crucial role in the development of new diagnostic and therapeutic methods. Her dedication to her field is further demonstrated by her ongoing involvement in academic mentorship, helping to train the next generation of scientists in nuclear sciences.

Impact and Influence 🌍

Prof. Dr. Yurt’s influence extends beyond her research and academic roles. As a leader in nuclear sciences, she has been instrumental in promoting the importance of nuclear applications in medicine and other fields. Her work has helped to bridge the gap between basic research and practical applications, ensuring that the benefits of nuclear science are realized in clinical settings.

Her leadership at the Institute of Nuclear Sciences has also been pivotal in shaping the research agenda in Turkey, encouraging interdisciplinary collaboration and fostering a culture of innovation. Under her guidance, the institute has strengthened its position as a center of excellence in nuclear research, attracting students and researchers from around the world.

Legacy and Future Contributions 🌟

Prof. Dr. Fatma Yurt’s legacy is one of dedication, innovation, and leadership. Her contributions to nuclear medicine, radiopharmacy, and related fields have had a lasting impact on both the scientific community and the broader healthcare sector. As she continues her work, her influence will undoubtedly grow, inspiring new research and leading to further advancements in nuclear applications.

🎓Publication 

An in vitro evaluation of Hypericum perforatum loaded-chitosan nanoparticle/agarose film as a Wound dressing

Unveiling combat strategies against Candida spp. biofilm structures: Demonstration of photodynamic inactivation with innovative phthalocyanine derivatives

Platinum (II) Schiff Base Complexes and their Effects on the Inhibition of Amyloid β1–42 Aggregation

In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer

  • Authors   :Tunçel, A., Maschauer, S., Prante, O., Yurt, F.
  • Journal    :Pharmaceuticals
  • Year         :2024